title: Buprenorphine versus methadone maintenance for the treatment of opioid dependence.
abstract: OBJECTIVE
  To evaluate the effectiveness of buprenorphine compared with methadone maintenance therapy in opiate addicts over a treatment period of 24 weeks.
  
  
  METHODS
  Subjects were randomized to receive either buprenorphine or methadone in an open, comparative study.
  
  
  METHODS
  Subjects were recruited and treated at the drug addiction outpatient clinic at the University of Vienna.
  
  
  METHODS
  Sixty subjects (19 females and 41 males) who met DSM-IV criteria for opioid dependence and were seeking treatment.
  
  
  METHODS
  Subjects received either sublingual buprenorphine (2-mg or 8-mg tablets; maximum daily dose 8 mg) or oral methadone (racemic D -/+ L-methadone; maximum daily dose 80 mg). A stable dose was maintained following the 6-day induction phase.
  
  
  METHODS
  Assessment of treatment retention and illicit substance use (opiates, cocaine and benzodiazepines) was made by urinalysis.
  
  
  RESULTS
  The retention rate was significantly better in the methadone maintained group (p < 0.05) but subjects completing the study in the buprenorphine group had significantly lower rates of illicit opiate consumption (p = 0.04).
  
  
  CONCLUSIONS
  The results support the superiority of methadone with respect to retention rate. However, they also confirm previous reports of buprenorphine use as an alternative in maintenance therapy for opiate addiction, suggesting that a specific subgroup may be benefiting from buprenorphine. This is the first comparative trial to use sublingual buprenorphine tablets: previously published comparison studies refer to 30% solutions of buprenorphine in alcohol.
authors.affiliation: Department of General Psychiatry, University Hospital of Vienna, Austria.
authors.forename: G
authors.initials: G
authors.lastname: Fischer
authors.forename: W
authors.initials: W
authors.lastname: Gombas
authors.forename: H
authors.initials: H
authors.lastname: Eder
authors.forename: R
authors.initials: R
authors.lastname: Jagsch
authors.forename: A
authors.initials: A
authors.lastname: Peternell
authors.forename: G
authors.initials: G
authors.lastname: Stühlinger
authors.forename: L
authors.initials: L
authors.lastname: Pezawas
authors.forename: H N
authors.initials: HN
authors.lastname: Aschauer
authors.forename: S
authors.initials: S
authors.lastname: Kasper
mesh_terms: D000293:Adolescent; D000328:Adult; D000553:Ambulatory Care; D000554:Ambulatory Care Facilities; D002047:Buprenorphine / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008691:Methadone / Q000627:therapeutic use*; D009294:Narcotics / Q000627:therapeutic use*; D009293:Opioid-Related Disorders / Q000534:rehabilitation*
chemical_list: D009294:Narcotics; D002047:Buprenorphine; D008691:Methadone